Merck sells API business, drug portfolio in $1B deal

06/28/2013 | Bloomberg · Pharmaceutical Business Review Online

Aspen Group agreed to buy Merck & Co.'s active pharmaceutical ingredient manufacturing business and purchase an option to buy a portfolio of 11 finished dose form molecules that target a range of conditions. The deal is valued at $1 billion. Aspen said the acquisition, which is expected to be finalized this year, will bolster its growth in Latin America, the Asia-Pacific region and other emerging markets.

View Full Article in:

Bloomberg · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA